Sonoma Pharmaceuticals, Inc. (SNOA)
NASDAQ: SNOA · Real-Time Price · USD
2.870
0.00 (0.00%)
At close: Jun 27, 2025, 4:00 PM
2.850
-0.020 (-0.70%)
After-hours: Jun 27, 2025, 4:56 PM EDT

Sonoma Pharmaceuticals Stock Forecast

Stock Price Forecast

There is currently no analyst price target forecast available for Sonoma Pharmaceuticals.

Price Target: $0.00 (0.00%)
Analyst Consensus: n/a
Target Low Average Median High
Price n/a n/a n/a n/a
Change n/a n/a n/a n/a

Analyst Ratings

There are currently no analyst ratings available for Sonoma Pharmaceuticals.

Recommendation Trends

Rating Jun '23Jul '23Aug '23Sep '23
Strong Buy 0000
Buy 0000
Hold 1110
Sell 0000
Strong Sell 0000
Total 1110

Latest Forecasts

Analyst Firm Rating Rating Action Price Target Upside Date
Ladenburg Thalmann
Ladenburg Thalmann
Strong Buy
Initiates
$65
Strong Buy Initiates $65 +2,164.81% Sep 5, 2023
Maxim Group
Maxim Group
Hold
Downgrades
n/a
Hold Downgrades n/a n/a Mar 6, 2018
Maxim Group
Maxim Group
Strong Buy
Maintains
$1,800$1,980
Strong Buy Maintains $1,800$1,980 +68,889.55% Nov 10, 2017
More Analyst Ratings

Financial Forecast

Revenue This Year
19.79M
from 14.29M
Increased by 38.54%
Revenue Next Year
n/a
from 19.79M
EPS This Year
-1.82
from -2.79
EPS Next Year
n/a
from -1.82
Fiscal Year FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 FY 2026
Period Ending Mar 31, 2021 Mar 31, 2022 Mar 31, 2023 Mar 31, 2024 Mar 31, 2025 Mar 31, 2026
Revenue
18.63M12.63M13.27M12.74M14.29M19.79M
Revenue Growth
3.91%-32.21%5.10%-4.05%12.20%38.54%
EPS
-39.58-38.34-30.35-10.63-2.79-1.82
EPS Growth
------
Forward PE
------
No. Analysts
-----3
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue 2026
High 20.4M
Avg 19.8M
Low 19.0M

Revenue Growth

Revenue Growth 2026
High
42.6%
Avg
38.5%
Low
33.1%

EPS Forecast

EPS 2026
High -1.88
Avg -1.82
Low -1.75

EPS Growth

EPS Growth 2026
High -
Avg -
Low -
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.